Digital Biomedical Assets
Digital Biomedical Assets come in many different forms, but generally fall under three categories:
Advances in Gene and Protein sequencing technology have led to an explosion of sequence data. These DBAs are the source of much of the fundamental research undertaken in Biomedicine today as they have become inexpensive to procure and curate.
Unlocking the information encoded in sequence data and understanding how this information is expressed in living biological systems holds the key to the development of future medicines, therapies and cures.
Clinical Data has always been and will remain the staple source of medical research. Notoriously difficult and costly to gather as well as being tightly regulated, it is unsurprising that this precious asset is underutilised.
At BiOMEX we hope to eliminate the barriers to the exchange of Clinical Data by leveraging technology from the financial sector which satisfies regulators and meets the demands of stringent compliance regimes..
Data on its own has little value without the means to analyse it. The vast quantities of data available today and in the future, present a unique opportunity to those that can create the algorithms, pipelines and workflows which enhance our understanding of biology.
Our role at BiOMEX is to create an infrastructure that will incentivise, identify and reward the creation of new analytic techniques and ensure they are made available to our participants.